scispace - formally typeset
R

Richard M. Hoffman

Researcher at Roy J. and Lucille A. Carver College of Medicine

Publications -  210
Citations -  10684

Richard M. Hoffman is an academic researcher from Roy J. and Lucille A. Carver College of Medicine. The author has contributed to research in topics: Prostate cancer & Population. The author has an hindex of 49, co-authored 197 publications receiving 9923 citations. Previous affiliations of Richard M. Hoffman include University of Arizona & University of New Mexico.

Papers
More filters
Journal ArticleDOI

Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer

TL;DR: Although a substantial proportion of men preferred AS, this was associated with anxiety and uncertainty, suggesting that this may be a difficult choice, and increasing the appropriate use of AS for low-risk prostate cancer will require additional reassurance and information.
Journal ArticleDOI

Mental Illness: Is there an Association With Cancer Screening Among Women Veterans?

TL;DR: Women with a mental illness are at risk for not adhering to recommended routine breast cancer Screening, and may require more intensive efforts to achieve optimal rates of recommended breast cancer screening.
Journal ArticleDOI

Patient Perspectives on Low-Dose Computed Tomography for Lung Cancer Screening, New Mexico, 2014

TL;DR: Patients with histories of heavy smoking who received care at a Federally Qualified Health Center and at a comprehensive cancer center-affiliated chest clinic in Albuquerque, New Mexico focused on perceptions about health screening, knowledge and attitudes about LDCT screening, and preferences regarding decision aids.
Journal ArticleDOI

DNA methylation age calculators reveal association with diabetic neuropathy in type 1 diabetes.

Delnaz Roshandel, +546 more
- 05 Apr 2020 - 
TL;DR: Pan-tissue and GrimAge were higher whereas Skin & Blood and PhenoAge were lower than chronological age and DNAm age was not associated with the risk of CVD or retinopathy over 18–20 years after DNAm measurement.